MRK vs PBYI · P/E 33, rev $16.61B vs P/E 4.3, rev $56.5M
Merck & Company Inc (MRK) versus Puma Biotechnology Inc (PBYI) — a side-by-side from cached financials, not a winner call.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Robert M. Davis J.D..
Puma Biotechnology Inc (PBYI) is a biotechnology company listed on US.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Latest reported PBYI revenue for 2026-06-30 was $56.5M. Net income was $8.2M. Revenue was up 26.1% from 2026-03-31 to 2026-06-30. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
MRK currently screens at market cap $285.12B and trailing P/E 32.5. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
Not investment advice. Open the MRK and PBYI stock pages for the full models.
Not investment advice.